Back

True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort

11 May 2024 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 10 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Miss Anouk Achten

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
Conventional medical therapies in patients with heart failure across different risk for transthyretin amyloid cardiomyopathy in the DELIVER, PARAGON-HF and TOPCAT Americas trials
Doctor R. Inciardi (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
The value of scoring systems in terms of phenogroups in the diagnosis of heart failure with preserved ejection fraction
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides Video
Presentation thumbnail
Inter-atrial block as a predictor of adverse outcomes in patients with HFpEF
Miss S. Mourmans (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction: the modifying role of obesity
Doctor P. Palau Sampio (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Associations of peroxiredoxin-4, a circulating antioxidant, with incident heart failure
Doctor N. Suthahar (Rotterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 10

The Event

Event poster

Heart Failure 2024

11 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Evaluating diagnostic scoring systems for early detection of transthyretin amyloidosis in patients with HFpEF and left ventricular hypertrophy
thumbnail
Congress Presentation
Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology
thumbnail
Congress Presentation
Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources